S and clinicopathological parameters. Table VI presents the methylation status ofONCOLOGY
S and clinicopathological parameters. Table VI presents the methylation status ofONCOLOGY LETTERS 12: 5145-5155,Table III. Diagnostic functionality of candidate genes. Gene BRCA1 GSTP1 Cathepsin B Protein supplier P16INK4A MGMT PTEN RAR2 CCND2 BC pos./total 17/70 22/70 28/70 19/70 34/70 39/70 47/70 BBD pos./total 0/20 0/20 4/20 5/20 8/20 8/20 9/20 Sensitivity 24.3 31.4 40.0 27.1 48.six 55.7 67.1 Specificity 100.0 100.0 80.0 75.0 60.0 60.0 55.0 AUC 0.621 0.657 0.600 0.511 0.543 0.579 0.611 95 CI 0.497-0.745 0.540-0.775 0.465-0.735 0.367-0.654 0.400-0.686 0.437-0.720 0.468-0.754 Pvalue 0.099 0.033 0.174 0.884 0.560 0.286 0.BC, breast cancer; BBD, benign breast disease; AUC, location beneath the curve; CI, self-assurance interval; pos., optimistic; BRCA1, breast cancer 1, early onset; DNA repair associated; GSTP1, glutathione S-transferase pi 1; P16INK4A, M-CSF Protein Biological Activity cyclin dependent kinase inhibitor 2A; MGMT, O-6methylguanine-DNA methyltransferase; PTEN, phosphatase and tensin homolog; RAR2, retinoic acid receptor beta 2; CCND2, cyclin D2.Table IV. Combination of BRCA1 and GSTP1 for the diagnosis of breast cancer. Cutpoint 0 1 2 LR, likelihood ratio.Sensitivity one hundred.0 44.three 11.4 0.Specificity 0.0 one hundred.0 one hundred.0 100.Appropriately classified 77.eight 56.7 31.1 22.LR+ 1.00 -LR 0.56 0.89 1.Table V. Mixture of seven candidate genes for the diagnosis of breast cancer. Cutpoint 0 1 2 3 four 5 6 LR, likelihood ratio.Sensitivity one hundred.0 94.3 82.9 58.six 38.6 14.three 5.7 0.Specificity 0.0 ten.0 45.0 80.0 95.0 one hundred.0 one hundred.0 100.Appropriately classified 77.8 75.six 74.4 63.3 51.1 33.3 26.7 22.LR+ 1.00 1.05 1.51 2.93 7.71 -LR 0.57 0.38 0.52 0.65 0.86 0.94 1.sufferers incorporated in the present study stratified by age, tumor size, histologic type, clinical stage, lymph node metastases, menopausal status and also the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal development element receptor 2 (HER2) and P53 in cancerous tissues. Hypermethylation of BRCA1 was demonstrated to be drastically more frequent in individuals with lymph node metastasis (P=0.025). Hypermethylation of P16 INK4A was substantially related with age (P= 0.015), menopausal status (P= 0.003) and P53 expression (P= 0.011). Hypermethylation of PTEN was drastically linked with menopausal status (P=0.027).RAR two hypermethylation was drastically extra prevalent in ER-negative (P= 0.002), PR-negative (P0.001) and P53-positive tumors (P=0.020). Association bet ween gene methylation and protein expression. Immunohistochemical evaluation was performed to assess the expression of BRCA1 and GSTP1. Together with the improve of methylation frequency, protein expression decreased drastically (P0.05; Table VII). Immunohistochemical staining benefits together together with the promoter methylation status of BRCA1 and GSTP1 are shown in Fig. three.Table VI. Correlation of DNA methylation and clinicopathological parameters.Qualities 8 (22.9) 27 (77.1) 9 (25.7) 26 (74.three) 9 (25.7) 26 (74.3) 14 (40.0) 21 (60.0) 19 (54.3) 16 (45.7) 10 (28.six) 25 (71.4) 0.122 0.015 0.788 6 (33.three) 12 (66.7) 8 (44.4) ten (55.six) six (33.three) 12 (66.7) 16 (30.8) 36 (69.2) 20 (38.five) 32 (61.5) 13 (25.0) 39 (75.0) 0.840 0.655 0.N BRCA1 GSTP1 P16INK4A MGMT PTEN RAR2 CCND2 ————————————– ———————————– ———————————– ————————————- ———————————– ———————————- ————————————M U M U M U M U M U M U M U 14 (40.0) 21 (60.0) 19 (54.three) 16 (45.7.